ALBO.OQ
Latest Trade
17.61USDChange
-0.27(-1.51%)Volume
14,372Today's Range
-
18.0552 Week Range
-
38.48As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 17.88 |
|---|---|
Open | 17.74 |
Volume | 14,372 |
3M AVG Volume | 1.13 |
Today's High | 18.05 |
Today's Low | 17.28 |
52 Week High | 38.48 |
52 Week Low | 16.26 |
Shares Out (MIL) | 12.69 |
Market Cap (MIL) | 226.81 |
Forward P/E | -2.99 |
Dividend (Yield %) | -- |
Albireo Pharma Q2 Loss Per Share $1.35
Albireo Provides Mid-Year Clinical Development Update
Albireo Pharma Reports Q1 Loss Per Share Of $1.39
Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).
Industry
Biotechnology & Drugs
Executive Leadership
David Chiswell
Independent Chairman of the Board
Ronald Harold Wilfred Cooper
President, Chief Executive Officer, Director
Simon N.R. Harford
Chief Financial Officer, Treasurer
Jan P. Mattsson
Chief Scientific Officer
Martha J. Carter
Chief Regulatory Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 86.31 |
Price To Book (MRQ) | 1.93 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -34.48 |
Return on Equity (TTM) | -32.73 |
* ALBIREO PHARMA INC FILES FOR NON-TIMELY 10-K WITH THE U.S. SEC Source text: (http://bit.ly/2pobWiJ) Further company coverage:
* ALBIREO REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS
* ALBIREO PRICES $65.0 MILLION PUBLIC OFFERING OF COMMON STOCK
* ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS
* ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN
* Albireo Pharma Inc - decision on potential approval of elobixibat in Japan expected in first half of 2018
* Final results of Albireo’s phase 2 study of A4250 in children with cholestatic liver disease presented at the liver meeting 2017
* Albireo Pharma Inc files for mixed shelf of up to $125 million - SEC filing Source text for Eikon: (http://bit.ly/2i8yKC7) Further company coverage:
* Albireo Pharma Inc - Jeffs replaces Denise Scots-Knight, who is departing from board Source text for Eikon: Further company coverage:
* EMA's paediatric committee agrees to Albireo’s a4250 pediatric investigation plan
* Albireo Pharma Inc - qtrly net loss per share diluted $0.86
* Albireo Pharma - unable to file 10-Q quarter ended June 30, 2017 in time due to unexpected delay in preparation of unaudited interim financial statements
* Perceptive Advisors LLC Reports 9.93 Pct Passive Stake In Albireo Pharma Inc as of May 24 - Sec Filing Source text for Eikon: Further company coverage:
* Muneer A. Satter reports 9.77 percent passive stake in Albireo Pharma Inc as of May 24, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2rkJUWZ) Further company coverage:
* Albireo prices $45.1 million public offering of common stock
* Albireo announces proposed public offering of common stock Source text for Eikon: Further company coverage:
* Qtrly loss per share $1.06 Source text for Eikon: Further company coverage:
* Expects that its current cash resources will be sufficient to meet its operating requirements at least through mid 2018
* Albireo announces submission of new drug application for Elobixibat in Japan
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.